ABSTRACT Objective: This integrative review article examines the efficacy of adoptive cell therapy using tumor-infiltrating lymphocytes, with a particular focus on the treatment of melanomas and other solid tumors. Methods: The methodology encompasses theme definition, comprehensive database searches, and a critical review of pertinent literature. Of the 1,947 articles initially identified, 15 were meticulously selected based on stringent inclusion and exclusion criteria. Results: The findings suggest that tumor-infiltrating lymphocytes-based therapy is particularly effective in treating metastatic melanomas, as noted by […]

ABSTRACT Natural Killer cells are immune leukocytes required for responses against tumor cells and virus-infected cells. In the last decade, natural killer cells have emerged as promising tools in cancer therapy, and clinical studies on patients treated with natural killer cells have revealed increased rates of disease-free survival. In this article, we review results from the major clinical trials that have used natural killer cells for cancer treatment, including their global distribution. We also discuss the major mechanisms of natural […]

Category: Thoracic Oncology Introduction: Despite the proven survival benefits of adjuvant systemic therapy (AT) in resected non-small-cell lung cancer (NSCLC), its underutilization remains a concern.(–) Objecitve: This study aims to explore the extent to which socioeconomic disparities influence AT underutilization. Methods: Data from the Brazilian Registry of Lung Cancer (2009-2023), was queried for patients with complete surgical resected stage IB-III and stratified based on AT delivery. Demographic, clinical, and pathological variables were evaluated. Logistic regression model was performed. The model’s […]

Category: Thoracic Oncology Introduction: Bronchogenic tumors, predominantly non-small cell type (NSCLC), are a global health concern, with adenocarcinomas, their most common subtype, being most often diagnosed at advanced stages, making it essential to develop effective therapeutic strategies, especially for patients with NSCLC who do not express the PD-L1 (Programmed Death-Ligand 1) protein. Two pivotal studies, Keynote-189() and Keynote-407,() presented their combined results in 2023, after a 5-year follow-up,() concluding that the combination of Pembrolizumab and chemotherapy demonstrated substantial improvements in […]

ABSTRACT Cemiplimab is a novel programmed death-1 inhibitor recently approved for advanced cutaneous squamous cell carcinoma. Immune-related adverse events derived from cemiplimab are similar to other anti-PD-1 drugs, including gastrointestinal and cutaneous toxicities. Oral immune-related adverse events were not reported with cemiplimab in previous studies; thus this case report warns of the fact that the oral cavity may be a site of immune-related adverse events during programmed death-1 block therapy and that this can lead to significant limitations when not […]

RESUMO A pneumonite secundária à imunoterapia é uma complicação rara, com incidência estimada em cerca de 3%. No entanto, trata-se de uma intercorrência de difícil diagnóstico e com grande morbidade, que tem se tornado um desafio para oncologistas e emergencistas. Foram revisados os casos de cinco pacientes que fizeram uso de anti-PD1 (program cell death receptor antagonist 1) para tratamento antineoplásico e que evoluíram com quadro de pneumonite induzida pelo tratamento. Todos os pacientes apresentaram sintomas respiratórios em vigência de […]